111 related articles for article (PubMed ID: 22034009)
21. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract][Full Text] [Related]
22. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
24. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
Heublein S; Anglesio MS; Marmé F; Kommoss S
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2251-2259. PubMed ID: 31385026
[TBL] [Abstract][Full Text] [Related]
28. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract][Full Text] [Related]
29. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer.
Wang Y; Liu P; Xu Y; Zhang W; Tong L; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Feb; 75(2):255-62. PubMed ID: 25428515
[TBL] [Abstract][Full Text] [Related]
30. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
32. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
Ho CK; Anwar S; Nanda J; Habib FK
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):94-6. PubMed ID: 19918264
[TBL] [Abstract][Full Text] [Related]
33. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.
Yang YC; Lu ML; Rao JY; Wallerand H; Cai L; Cao W; Pantuck A; Dalbagni G; Reuter V; Figlin RA; Belldegrun A; Cordon-Cardo C; Zhang ZF
Br J Cancer; 2006 Dec; 95(11):1455-8. PubMed ID: 17088904
[TBL] [Abstract][Full Text] [Related]
34. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
[TBL] [Abstract][Full Text] [Related]
35. Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma.
Tsay MD; Hsieh MJ; Lee CY; Wang SS; Chen CS; Hung SC; Lin CY; Yang SF
Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31878098
[TBL] [Abstract][Full Text] [Related]
36. Association of Fibroblast Growth Factor Receptor 4 Genetic Polymorphisms With the Development of Uterine Cervical Cancer and Patient Prognosis.
Chen TH; Yang SF; Liu YF; Lin WL; Han CP; Wang PH
Reprod Sci; 2018 Jan; 25(1):86-93. PubMed ID: 28378614
[TBL] [Abstract][Full Text] [Related]
37. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
38. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
39. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
[TBL] [Abstract][Full Text] [Related]
40. The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients.
Ye YW; Zhang X; Zhou Y; Wu J; Zhao C; Yuan L; Wang G; Du C; Wang C; Shi Y
J Surg Oncol; 2012 Dec; 106(7):872-9. PubMed ID: 22585711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
